Skip to main content
Premium Trial:

Request an Annual Quote

NeuMoDx Gets FDA Emergency Use Authorization for Coronavirus Test

NEW YORK – NeuMoDx received Emergency Use Authorization from the US Food and Drug Administration on Monday for a COVID-19 assay on its fully automated, mid- and high-throughput diagnostics systems, according to a document posted on the agency's website.

Called the NeuMoDx SARS-CoV-2 Test Strip, the assay was authorized for the NeuMoDx 288 Molecular and NeuMoDx 96 molecular systems. It detects SARS-CoV-2 in nasal, nasopharyngeal, and oropharyngeal swab samples from patients suspected of having COVID-19, the disease caused by SARS-CoV-2 infection. The mulitplexed test detects the Nsp2 gene and the N gene of the virus, and the time to first results on the instrument is approximately 80 minutes 

The NeuMoDx systems are continuous, random-access analyzers that incorporate a proprietary dried reagent format, magnetic particle affinity capture, and real-time PCR, in a multi-sample microfluidic cartridge-based system. 

In 2018, NeuMoDx entered a partnership and milestone-based merger agreement with Qiagen, a firm that Thermo Fisher Scientific now plans to acquire. Qiagen also received EUA on Monday for its QIAstat-Dx Respiratory SARS-CoV-2 Panel.

The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.